Clinical trials
Lung Cancer Stage I clinical trials
Below are recruiting lung cancer stage i clinical trials, each written for real people, not researchers. We’re tracking 1,117 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07161388Recruiting
Durvalumab after chemoradiation for limited-stage small cell lung cancer
This trial tests long-term use of durvalumab (an immunotherapy drug) after standard chemotherapy and radiation for limited-stage small cell lung cancer. It may keep the cancer from coming back.
BeijingAges 18 years+ - NCT06765616RecruitingPhase 2
Immunotherapy with chemo and radiation for rectal cancer before surgery
This trial tests a combination of a PD-L1 inhibitor (adebrelimab), short-course radiation, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Jinan, ShandongAges 18–85 - NCT07120282RecruitingPhase 2
Tislelizumab after surgery for early-stage lung cancer
This trial tests whether a drug called tislelizumab, given after surgery, can help prevent lung cancer from coming back. It is for people with stage I non-small cell lung cancer who have certain high-risk features and a protein called PD-L1 on their tumor cells.
BeijingAges 18 years+ - NCT04691817RecruitingPhase 1/Phase 2
Testing tocilizumab plus atezolizumab after lung cancer treatment failure
This trial studies whether combining tocilizumab with atezolizumab can help people with advanced lung cancer that has already stopped responding to an immune checkpoint medicine. It may help when standard immune therapy (and other treatments) aren’t working anymore.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05623267RecruitingPhase 2/Phase 3
SugeMalimab after lung radiation and chemotherapy for limited-stage SCLC
This trial tests sugemalimab as “extra treatment” after standard chemoradiation for limited-stage small cell lung cancer. It aims to lower the chance of the cancer coming back by helping the immune system stay active after initial therapy.
Guangzhou, GuangdongAges 18 years+ - NCT05332925Recruiting
Tumor samples grown in dishes to predict immunotherapy response
This study takes small biopsy samples of your lung cancer and grows them in a dish to predict how well immunotherapy will work. If you qualify, you’ll receive standard immunotherapy (anti-PD-1/L1, with or without anti-CTLA-4), and the results from the dish-grown tumors will be compared to your real-world response.
Fairway, KansasAges 18–110 - NCT07564401RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Advanced Lung Cancer
This study tests DJI136, a new type of cell therapy that trains your immune cells to fight small cell lung cancer. The therapy targets a protein called DLL3 found on cancer cells. It's designed for patients whose cancer has returned or progressed after initial chemotherapy and immunotherapy.
Lexington, KentuckyAges 18 years+ - NCT07245446RecruitingPhase 2
Ivonescimab for untreated extensive-stage SCLC
This study tests a new immunotherapy drug called ivonescimab for people with extensive-stage small cell lung cancer who have not had treatment before. The goal is to see if it can help shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–75 - NCT07113691RecruitingPhase 1
Experimental drug plus radiation and immunotherapy for lung cancer
This study tests a combination of three treatments for extensive-stage small cell lung cancer that has worsened after initial chemotherapy: an experimental pill, focused radiation (SBRT), and an immunotherapy drug. The goal is to see if this triple therapy can help the immune system fight the cancer more effectively.
New Haven, ConnecticutAges 18 years+ - NCT06497530RecruitingPhase 2
Lurbinectedin with serplulimab for extensive-stage SCLC maintenance
This trial tests a combination of two drugs, lurbinectedin and serplulimab, as maintenance therapy after initial chemotherapy for people with extensive-stage small cell lung cancer (SCLC) that hasn't spread to the brain. The goal is to see if this approach helps keep the cancer from growing for longer.
Guangzhou, GuangdongAges 18 years+ - NCT07149649RecruitingPhase 2/Phase 3
Magnesium for advanced lung cancer
This trial tests if adding magnesium supplements to standard first-line treatment (chemotherapy plus immunotherapy) improves outcomes for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be removed by surgery. It is for patients who have not had prior treatment for metastatic disease.
AarauAges 18 years+ - NCT06561386RecruitingPhase 3
Testing a new drug combo for advanced lung cancer
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Mobile, AlabamaAges 18 years+ - NCT06436625Recruiting
Outpatient rehab for lung cancer patients on immunotherapy
This study tests whether a structured outpatient exercise program can help people with non-small cell lung cancer who are already receiving immunotherapy. It is designed for those whose cancer is stable or responding after initial treatment.
ViennaAges 18–120 - NCT07371663RecruitingPhase 1/Phase 2
TCC1727 combination therapy for advanced solid tumors
This trial tests a new drug, TCC1727, combined with other treatments for people with advanced solid tumors that have stopped responding to standard therapy. It aims to see if these combinations can help shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06528743Recruiting
Testing primer shot radiotherapy for lung cancer
This study is testing a new way of giving a very short, high-dose radiation treatment (called 'primer shot' radiotherapy) for people with non-small cell lung cancer. The goal is to see if it’s safe and practical for shrinking the main lung tumor and relieving symptoms.
AmsterdamAges 18 years+ - NCT05857800Recruiting
Studying how lung tumor treatment affects the tumor environment
This trial studies how “before-surgery” (neoadjuvant) lung cancer treatments change the tumor environment by monitoring patients during care. It may help doctors better choose therapies and predict who benefits from treatment.
ShanghaiAges 18 years+ - NCT06421298RecruitingPhase 2
Tafolecimab and sintilimab plus chemo for advanced lung cancer
This trial is testing a new combination of treatments, including an immune drug (sintilimab) and a cholesterol-lowering drug (tafolecimab), along with chemotherapy, for people with advanced lung cancer that no longer responds to standard immunotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT07680790RecruitingPhase 3
New drug combination for advanced egfr lung cancer
This study tests a new drug (izalontamab brengitecan) combined with a standard targeted therapy (osimertinib) compared to standard treatments alone for advanced EGFR-mutant non-small cell lung cancer. It aims to see if the combination works better.
Beverly Hills, CaliforniaAges 18 years+ - NCT07221474RecruitingPhase 2
Study of a personalized vaccine plus chemo for lung cancer
This trial tests an experimental personalized cancer vaccine (V940) combined with pembrolizumab and chemotherapy for people with advanced squamous non-small cell lung cancer that has spread. The goal is to see if adding the vaccine helps the immune system fight the cancer better.
Tampa, FloridaAges 18 years+ - NCT07164885Recruiting
RAPART trial for advanced lung cancer patients
This trial tests a treatment for stage 3 lung cancer that cannot be removed with surgery. It includes people who have had other treatments before, like chemo or immunotherapy.
Shenzhen, GuangdongAges 18 years+ - NCT06311981RecruitingPhase 2
Carbon ion radiation for elderly lung cancer patients
This trial tests carbon ion radiotherapy for adults 75 and older with locally advanced non-small cell lung cancer who cannot have surgery. The goal is to see if this precise type of radiation can treat the cancer effectively with fewer side effects.
Shanghai, Shanghai MunicipalityAges 75 years+ - NCT06883136Enrolling by invitation
Sintilimab plus chemo for elderly advanced lung cancer
This trial tests a combination of the immunotherapy drug sintilimab plus standard chemotherapy (platinum-based doublet) as the first treatment for older adults (60–80) with advanced non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach works better than chemotherapy alone.
Jinan, ShandongAges 60–80 - NCT06784791RecruitingPhase 2
Amivantamab before surgery for EGFR-mutant lung cancer
This trial tests a new drug, amivantamab, given before surgery for people with a specific EGFR-mutated lung cancer. It aims to shrink tumors and improve surgical outcomes, and may be combined with standard chemotherapy in some patients.
HasseltAges 18 years+ - NCT06775743RecruitingPhase 2
Combination therapy and radiation for EGFR-mutant lung cancer after resistance
This trial tests whether adding radiation therapy to a drug combination can help people with a specific type of lung cancer that has stopped responding to standard first-line pills. It's for patients whose cancer has a certain gene change (EGFR) and has spread to other parts of the body.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Lung Cancer Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer stage i?
- Yes. Clin2 currently lists 1,117 recruiting lung cancer stage i studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer stage i trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer stage i trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.